

Review Article

Metabolic Syndrome and Diabetes: A Review

Abdoljalal Marjani¹

¹Metabolic Disorders Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

ABSTRACT

The prevalence of metabolic syndrome is increasing worldwide. Several factors such as hyperglycemia are associated with risk of developing metabolic syndrome. Metabolic syndrome is a clinical tool for identification of subjects at risk of diseases such as type 2 diabetes mellitus, which could be a predictor of metabolic syndrome. There may be an association between diabetes, metabolic syndrome and cardiovascular morbidity and mortality. This study aimed to review the literature on diabetes, as a component of metabolic syndrome.

KEYWORDS: Metabolic syndrome; Diabetes; Diseases

Correspondence: Abdoljalal Marjani, Metabolic Disorders Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran, Telephone: +981732421651, Email: abdoljalal@yahoo.com

INTRODUCTION

Metabolic syndrome (MetS) is a major public-health problem worldwide. It increases the risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) by 5- and 2-fold, respectively [1]. Many studies have shown that patients with MetS are at greater risk of stroke (2-4 fold), myocardial infarction (3-4 fold) and mortality (2-fold) compared to those without the syndrome [2]. In 1920, Kylin, a Swedish physician, showed the association of hypertension, hyperglycemia and gout [3]. In 1947, Vague indicated that visceral obesity is associated with metabolic disorders in patients with CVD and T2DM [4]. In 1965, Avogaro and Crepaldi revealed a syndrome that included hypertension, hyperglycemia and obesity [5]. In 1988, Reaven demonstrated "Syndrome X" as a concept of insulin resistance [6]. In 1989, Kaplan introduced the syndrome "The Deadly Quartet", which is due to upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension [7]. In 1992, Haffner introduced "The Insulin Resistance Syndrome" [8].

There are several criteria for diagnosis of

MetS [9]. The World Health Organization (WHO) in 1998 and European Group for the Study of Insulin Resistance in 1999 provided definitions for MetS [10, 11]. The National Cholesterol Education Program-Adult Treatment Panel (NCEP/ATP) in 2001 [12], the American Association of Clinical Endocrinologists in 2003 [13] and the International Diabetes Federation (IDF) in 2005 [14] also reported their definitions. It has believed that high prevalence of MetS is the reason for more recent study. Many studies have shown that the worldwide prevalence of MetS ranges from almost 10% to 84%. The prevalence of MetS is affected by geographic location, sex, age, race, sedentary lifestyle, high body mass index and ethnicity [15, 16]. Study of Cameron et al. indicated that the prevalence of MetS and its components is associated with genetic background, diet, levels of physical activity, smoking, family history of diabetes, and education level [17]. Age-related study of Park et al. have revealed that the prevalence of MetS ranges from 20 to 70 years in males and females [18], while findings of Ponzolzer et al. showed that prevalence of MetS ranges from 32.6% to 41.5% among

postmenopausal females [19]. Study of Marjani et al. showed that the prevalence of MetS in patients with T2DM is higher in females (53.27%) than in males (48.71%) [20]. Marjani et al. also indicated that the frequency of MetS in T2DM patients was 75.42% and 76.79% according to ATPIII and IDF diagnostic criteria, respectively. In addition, females have been affected more than men according to both criteria [21]. The frequency of MetS in Fars and Sistani ethnic groups in Gorgan (Iran) was 20.62% and 23.75%, respectively [22,23]. The prevalence of MetS in Korean and Chinese females was 13.8% [24] and 17.8% [25], respectively. Studies of Eshtiaghi [26], Ainy [27], Deilbert [28], Figueiredo Neto [29] and Heidari et al. [30] indicated that the prevalence of MetS is 18.3%, 53%, 23%, 24% and 44.9%, respectively. The aim of this study was to review the literature on the association of diabetes with MetS.

Diabetes, a component of MetS

T2DM is a chronic and fatal disease with an increasing prevalence worldwide [31]. MetS is a clinical tool for identification of subjects at risk of some diseases such as CVD and T2DM. Several factors may lead to development of MetS [32]. MetS is associated with insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, hypertension, thrombophilia, and chronic stress [33]. According to the WHO, diabetes is defined as fasting plasma glucose of ≥ 7.0 mmol/l (126 mg/dl) or 2-h venous plasma glucose ≥ 11.1 mmol/l (200 mg/dl) following ingestion of 75 g oral glucose load [34]. The number of patients with T2DM worldwide has been estimated to increase to 300 million by 2025 [35].

High glucose level is a component of MetS [1, 36]. Many studies have reported insulin resistance as a risk factor for MetS [37]. It is well demonstrated that insulin resistance

causes hyperglycemia. A study has shown that insulin resistant was considered in most subjects with the MetS [38]. Moreover, there seems to be an association between MetS and pre-diabetes. In addition, MetS increases the risk of developing diabetes by 5-fold [39]. Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) in patients with MetS may also increase the risk of developing diabetes. Some findings have indicated that MetS without diabetes may increase the risk of diabetes by almost 5-fold, whereas in patients with IFG or IGT, the risk of diabetes is 5- to 7-fold higher compared to subjects with normal blood glucose [40]. Thus, there may be an association between IFG or IGT, MetS and the increased risk of diabetes. Diabetologists believe that diabetes is a risk factor for CVD and microangiopathic disease. CVD is the most important complication of diabetes. It is accounted for up to 80% of the macrovascular complications [41,42]. Diabetic patients also have higher risk of developing hypertension, dyslipidemia, and obesity. They may also be at risk of coronary heart disease, stroke, and peripheral vascular disease along with retinopathy, chronic kidney disease, bladder dysfunction, erectile dysfunction, orthostatic hypotension, gastroparesis, and skin disorders [33]. Studies have revealed that there is an association between increased glucose level and incidence of microangiopathy (diabetic nephropathy, retinopathy, and neuropathy). Many molecular mechanisms have been suggested to explain the effect of increased glucose levels in microangiopathy. These mechanisms include protein kinase C activation, formation of advanced glycation end products, formation of reactive oxygen species, flux through the hexosamine pathway, the polyol pathway induction, overexpression of growth factors and inflammatory cytokines, and defective

insulin signaling [43, 44]. The prevalence of metabolic disorders is increasing worldwide [45]. Several risk factors are associated with this increase [46]. MetS with or without diabetes, is a predictor of coronary heart disease and premature mortality [47-49]. In diabetic patients, MetS is considered a risk factor for chronic microvascular complications [47-48, 50-52]. Some studies have shown association of MetS and microvascular complications in diabetics [53, 54].

Clinical identification of MetS patients is important for management and treatment to reduce the potential risk of subsequent diseases [55]. Lifestyle changes, primarily weight loss, change in diet, exercise, and pharmacological treatment are effective for controlling the risk of complications [56]. However, the clinical management of patients with MetS is not easy. This may be due to lack of a known method for prevention or improvement of all risk factors (components of MetS) of MetS.

Physicians use different methods to treat each component of MetS. For example, drug therapy is used to reduce blood pressure, blood glucose, and triglycerides. Lifestyle modification is another method that can be advised by physicians and dieticians [57]. Although the impact of lifestyle modification is less than that of drug therapy, it can be useful for controlling the metabolic risk factors [58]. Weight loss is also suggested for treatment of patients with MetS, which can be carried out by limiting calorie intake, behavioral change, physical activity and anti-obesity medications [58]. Studies have shown that weight loss can lower blood pressure, affect lipid profile (decrease triglyceride and increase high-density lipoprotein levels), and improve insulin resistance [59-60]. Weight loss could also reduce fasting blood glucose, insulin, hemoglobinA1c levels, and contribute to abdominal fat loss [61, 62]. It seems to

improve an unusual component of MetS and limit the progression of diabetes [63]. According to the Finnish Diabetes Prevention Study [64] and the US Diabetes Prevention Program [65], diet and exercise have significant effects on the progression of IGT to T2DM. Some studies have revealed association of hyperlipidemia and hyperglycemia (the components of the MetS) with low glycemic index foods [66], while the prevalence of insulin resistance and MetS is associated with high glycemic index foods [67].

Implementation of treatment guidelines provided by the NCEP [68], the seventh Joint National Commission for treatment of high blood pressure [69], the American Diabetes Association [70], the American Heart Association [36], and the National Institute of Health Obesity Initiative [71] could also be used to prevent risk factors of MetS.

CONCLUSION

Several factors can prevent the development of MetS. T2DM is suggested as a predictor of MetS. There is an association between diabetes, MetS and cardiovascular morbidity and mortality.

REFERENCES

1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and international association for the study of obesity. *Circulation*. 2009; 120 (16): 1640–1645.
2. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome — a new worldwide definition. *The Lancet*. 2005; 366

(9491):1059–1062.

3. Kylin E. Studienueber das Hypertonie-Hyperglyca “mie-Hyperurika” miesyndrom. ZentralblattfuerInnereMedizin. 1923; 44: 105–127.

4. Vague J. Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale. 1947; 30: 339–340.

5. Avogaro P and G. Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965; 1: 137.

6. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37 (12):1595–1607.

7. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989; 149 (7): 1514–1520.

8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA and Stern MP. Prospective analysis of the insulinresistance syndrome (Syndrome X). Diabetes. 1992; 41 (6):715–722.

9. Eckel RH, Grundy SM and Zimmet PZ. The metabolic syndrome. The Lancet. 2005; 365 (9468):1415–1428.

10. Alberti KG and Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998; 15(7): 539–553.

11. Balkau B and Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine. 1999; 16 (5): 442–443.

12. Cleeman JJ. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association. 2001; 285 (19): 2486–2497.

13. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine Practice. 2003; 9 (3): 237–252.

14. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, 2005; <http://www.idf.org/metabolic-syndrome>.

15. Desroches S and Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Applied Physiology, Nutrition and Metabolism. 2007; 32 (1): 23–32.

16. Kolovou GD, Anagnostopoulou KK, SalpeaKD, and Mikhailidis DP. The prevalence of metabolic syndrome in various populations. The American Journal of the Medical Sciences. 2007; 333 (6): 362–371.

17. Cameron AJ, Shaw JE and ZimmetPZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004; 33 (2): 351–375.

18. Park Y-W, Zhu S, Palaniappan L, Heshka S, CarnethonMR, and Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Archives of Internal Medicine. 2003; 163 (4): 427–436.

19. Ponholzer A, Temml C, Rauchenwald M, Marszalek M, and Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women? International Journal of Impotence Research. 2008; 20 (1):100–104.

20. Marjani A, Mojerloo M. The metabolic syndrome in type 2 diabetic subjects in Gorgan, Iran. J Pak Med Assoc. 2011;61(5):458-461.

21. Marjani A and Shirafkan A. The Metabolic Syndrome in Type 2 Diabetic

Patients in Gorgan: According To NCEP ATP III and IDF Definitions. *Advances in Biological Research*. 2011; 5 (4): 200-205.

22. Marjani A, Hezarkhani S and Shahini N. Prevalence of Metabolic Syndrome among Fars Ethnic Women in North East of Iran. *World Journal of Medical Sciences*. 2012; 7(1): 17-22.

23. Marjani A, Shahini N, AghAtabay O, GhiyasTabari R. Prevalence of Metabolic Syndrome among Sistane Ethnic Women. *Advanced Studies in Biology*. 2012; 8: 363 – 372.

24. Kim HM, Park J, Ryu SY, Kim J. The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey. *Diabetes Care*. 2007; 30(3):701-706.

25. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, et al. Prevalence of the metabolic syndrome and overweight among adults in China. *Lancet*. 2005;365(9468):1398-1405.

26. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. *Maturitas*. 2010;65(3):262-266.

27. Ainy E, Mirmiran P, ZahediAsl S, Azizi F. Prevalence of metabolic syndrome during menopausal transition Tehranian women: Tehran Lipid and Glucose Study (TLGS). *Maturitas*. 2007;58(2):150-155.

28. Deibert P, Konig D, VitolinsMZ, Landmann U, Frey I, Zahradnik HP, Berg A. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. *Nutrition Journal*. 2007;6 (1):31.

29. Figueiredo Neto JA, Figueiredo ED, Barbosa JB, Barbosa Fd, Costa GR, Nina VJ, Nina RV. Metabolic syndrome and menopause: cross-sectional study in gynecology clinic. *Arquivos Brasileiros de Cardiologia*. 2010;95(3):339-345.

30. Heidari R, Sadeghi M, Talaei M, Rabiei

K, Mohammadifard N, Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. *DiabetolMetabSyndr*. 2010; 2: 59.

31. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, et al. Racial differences in the relation between blood pressure and insulin resistance. *New England Journal of Medicine*. 1991;324(11):733–9.

32. Bentley-Lewis R, Koruda K, SeelyEW. The metabolic syndrome in women. *Nature clinical practice. Endocrinology & metabolism*. 2007;3(10):696–704.

33. Grundy SM. Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. *Journal of the American College of Cardiology* 2012; 59 (7): 635–43

34. American Diabetes Association. Standards of medical care in diabetes-2008. *Diabetes Care*. 2008;31 Suppl 1:S12-54.

35. Zimmet P, Alberti KG, Shaw S. Global and societal implications of diabetes epidemic. *Nature*. 2001;414 (6865):782-7.

36. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (erratum in: *Circulation*. 2005; 112:2735–52.

37. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. *Panminerva Medica*. 2005;47:201–10.

38. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr., Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. *Diabetes*. 2003;52:2740 –7.

39. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2

diabetes and/or cardiovascular disease? *Diabetes Care*. 2004;27 (11):2676–81.

40. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. *Diabetes Care*. 2007; 30 (1): 8–13.

41. Lebovitz HE. Insulin resistance: a common link between type 2 diabetes and cardiovascular disease. *Diabetes, Obesity and Metabolism*. 2006;8 (3):237–49.

42. Thomas JE, Foody JM. The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. *Journal of the CardioMetabolic Syndrome*. 2007;2(2):108–13.

43. He Z, King GL. Microvascular complications of diabetes. *Endocrinology and Metabolism Clinics of North America*. North Am 2004;33 (1) :215–38, xi–xii.

44. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. *Cell Tissue Research*. 2009;335 (1):165– 89.

45. American Diabetes Association. Standards of medical care in diabetes – 2013. *Diabetes Care* 2013;36(Suppl. 1):S11–66.

46. Wang YW, Sun GD, Sun J, Liu SJ, Wang J, XuXH, et al. Spontaneous Type 2 diabetic rodent models. *Journal of Diabetes Research*. 2013. <http://dx.doi.org/10.1155/2013/401723>.

47. Metascreen Writing Committee, Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A: The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. *Diabetes care*. 2006; 29 (12):2701–07.

48. Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, et al. Cardiometabolic Risk Profiles Associated with Chronic Complications in Overweight and Obese Type 2 Diabetes Patients in South China. *PLoS ONE*. 2014; 9(7): e101289.

49. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. *Diabetologica*. 2001; 44 (9):1148–54.

50. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. *Israel Medicine Association Journal*. 2006; 8 (6):378–82.

51. Raman R, Gupta A, Pal SS. Prevalence of MS and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. *Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 14)*. *Diabetology and metabolic syndrome*. 2010; 2:67.

52. Pang C, Jia L, Hou X, Gao X, Liu W, Bao Y, et al. The Significance of Screening for Microvascular Diseases in Chinese Community-Based Subjects with Various Metabolic Abnormalities. *PLoS ONE*. 2014;9(5):e97928.

53. Iwasaki T, Togashi Y, Ohshige K. Neither the presence of MS as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular normoarterial complications in Japanese patients with type 2 Diabetes. *Diabetes Research Clinical Practice* 2008;79(3):427–32.

54. Carole AC, Christine CJ, Retnakaran R, Holman RR. Impact of the metabolic syndrome Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus United Kingdom Prospective Diabetes Study 78. *Circulation*.

2007;116:2119-2126.

55. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. *Preventive Cardiology*. 2005; 8 (1): 47–54.

56. Deen D. Metabolic syndrome: time for action. *The American Family Physician*. 2004; 69 (12): 2875–2887.

57. Bellentani S, Grave RD, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. *Hepatology*. 2008; 47 (2): 746–754.

58. Donato KA. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. *Archives of Internal Medicine*. 1998; 158 (17): 1855–1867.

59. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. *Diabetes Care*. 2003; 26 (3): 557–562.

60. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. *International Journal of Obesity*. 1997; 21(supplement 1): S5–S9.

61. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. *Archives of Internal Medicine*. 1987; 147 (10): 1749–1753.

62. Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. *Obesity Research*. 2004; 12 (5): 789–798.

63. Haslam DW and James WPT. Obesity. *The Lancet*. 2005; 366 (9492): 1197–1209.

64. Toumiheto J, Lindstrom J, Eriksson JG, VaLLe TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes
JCBR. 2017; 1(2):36-43

mellitus with lifestyle intervention or metformin. *The New England Journal of Medicine* 2001; 344 (18): 1343–1350.

65. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RE, Lachin JM, Walker EK, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *The New England Journal of Medicine*. 2002; 346 (6): 393–403.

66. Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A, et al. Glycemic index: overview of implications in health and disease. *The American Journal of Clinical Nutrition* 2002; 76 (1): 266S–273S.

67. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PWF, and Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. *Diabetes Care*. 2004; 27 (2): 538–546.

68. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. *Circulation*. 2002; 106 (25): 3143–3421.

69. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. *Journal of the American Medical Association*. 2003; 289 (19): 2560–2572.

70. American Diabetes Association. Clinical practice recommendations 2005. *Diabetes Care*. 2005; 28 (supplement 1): S1–79.

71. Clinical Guidelines on the Identification, Evaluation, and Treatment of

Overweight and Obesity in Adults. The Evidence Report. National Institutes of Health. Obesity Research. 1998; 6(supplement 2): 51S–209S.